The development of sustainable replacements for fossil fuels has been spurred by concerns over global warming effects. Biofuels are typically produced through fermentation of edible crops, or forest or agricultural residues requiring cost-intensive pretreatment. An alternative is to use photosynthetic cyanobacteria to directly convert CO2 and sunlight into fuel. In this thesis, the cyanobacterium Synechocystis sp. PCC 6803 was genetically engineered to produce the biofuel n­-butanol. Several metabolic engineering strategies were explored with the aim to increase butanol titers and tolerance. In papers I-II, different driving forces for n-butanol production were evaluated. Expression of a phosphoketolase increased acetyl-CoA levels and subsequently butanol titers. Attempts to increase the NADH pool further improved titers to 100 mg/L in four days. In paper III, enzymes were co-localized onto a scaffold to aid intermediate channeling. The scaffold was tested on a farnesene and polyhydroxybutyrate (PHB) pathway in yeast and in E. coli, respectively, and could be extended to cyanobacteria. Enzyme co-localization increased farnesene titers by 120%. Additionally, fusion of scaffold-recognizing proteins to the enzymes improved farnesene and PHB production by 20% and 300%, respectively, even in the absence of scaffold. In paper IV, the gene repression technology CRISPRi was implemented in Synechocystis to enable parallel repression of multiple genes. CRISPRi allowed 50-95% repression of four genes simultaneously. The method will be valuable for repression of competing pathways to butanol synthesis. Butanol becomes toxic at high concentrations, impeding growth and thus limiting titers. In papers V-VI, butanol tolerance was increased by overexpressing a heat shock protein or a stress-related sigma factor. Taken together, this thesis demonstrates several strategies to improve butanol production from cyanobacteria. The strategies could ultimately be combined to increase titers further.

Clustered regularly interspaced short palindromic repeats (CRISPR) are derived from a bacterial and archaeal adaptive immune system. The core enzymes of CRISPR are RNA-guided endonucleases that sequence-specifically cleave foreign double-stranded DNA. Improving and controling the properties of the CRISPR system is a crucial step in advancing the therapeutic potential of CRISPR technology. Several classes of these enzymes exist and are being adapted for biotechnology, such as genome engineering. Cas12a (Cpf1) is a Type V CRISPR-associated (Cas) enzyme that naturally uses only one guide RNA, in contrast to Type II CRISPR-Cas9 enzymes. Thus, Cpf1 may represent a simpler, more practical tool for applications such as gene editing and therapeutics. This dissertation comprises four related studies in this area. To better understand the functional requirements for Cpf1-crRNA interaction and develop modified crRNAs suitable for synthetic biology and therapeutic applications, the first study performed nucleotide substitutions in the crRNA. It focused on the protein-interaction motif of the crRNA by incorporating base changes at the 2ʹ position that alter hydrogen-bonding capacity, sugar pucker, and flexibility. DNA substitutions in RNA can probe the importance of A-form structure, 2ʹ-hydroxyl contacts, and conformational constraints within RNA-guided enzymes. In addition, Chemical modifications include 2'-deoxy, 2'-fluoro, 2'- deoxy-arabinonucleic acid, and oxepane. Our study discovered that 2'-fluoro maintains the A-form structure and is compatible with AsCpf1 activity. Biochemical endonuclease activity, gene editing efficiency, Cpf1 binding affinity, and ribonucleoprotein stability were used to assess the tolerance and effects of modification. Characterizing structure-function requirements for Cpf1-crRNA interaction will facilitate better design and tuning of Cpf1 enzymes. The second study established a FRET-based assay in collaboration with a computational collaborator to identify small molecule inhibitors predicted by virtual docking and simulations. This study aims to lay the foundation for efficient, safe implementation of CRISPR-Cpf1. The third study used chemically modified Cas9-guide RNAs to offset known weaknesses of CRISPRi. It takes advantage of the high binding affinity and nuclease resistance of modified guides to potentially reduce the required components for CRISPRi.

Mycobacterial species are diverse organisms, classified into tuberculous and nontuberculous mycobacteria (NTM). Mycobacterium tuberculosis has been thoroughly investigated, but pathogenic NTM have not. The identified technology gap for studying potential antibiotic targets across mycobacteria is that there is not a tool developed for efficiently creating bacterial clones containing these genes with a reporter system to evaluate CRISPR interference (CRi) knockdowns. CRi is a quick and simple way to silence genes. In this study, Golden Gate (GG) cloning compatible Lux reporter plasmids were engineered for the efficient cloning of target genes as transcriptional fusions with luxAB, a luminescent reporter, for use with CRi. Additionally, a CRi plasmid was designed with a Giles integration site so that it could be integrated into the mycobacterial genome with the reporter plasmid, but at a different location. Based on current research, it seems that mycobacterial L,D-transpeptidase enzymes (Ldts), involved in peptidoglycan synthesis, are potential targets for the drug class known as β-lactams and should be further explored. Ldt 2 is of particular interest as research indicates that it may be involved in pathogenicity; therefore, GG cloning of M. smegmatis (Msm) Ldt 2 was performed using the designed GG plasmid. Constructing the GG plasmid (pMV306hsp+luxG13, GG pMV) as well as the CRi + Giles integration plasmid (pLJR962 + pML1357, CRi + Giles) was successful; however, the evaluation of the luminescent reporter with CRi knockdown has yet to be performed.

京都大学 / 新制・課程博士 / 博士(医科学) / 甲第25203号 / 医科博第159号 / 新制||医科||10(附属図書館) / 京都大学大学院医学研究科医科学専攻 / (主査)教授 濵﨑 洋子, 教授 中川 一路, 教授 竹内 理 / 学位規則第4条第1項該当 / Doctor of Agricultural Science / Kyoto University / DFAM

RNA-bindande proteiner (RBP:er) har framträtt som kritiska regulatorer i post-transkriptionell genreglering, och deras dysreglering bidrar till cancerpatogenes. CAPRIN1, ett cytoplasmiskt protein, har identifierats som ett onkofetalt RBP med potentiell betydelse i hepatocellulärt karcinom (HCC), en mycket malign form av levercancer med dålig prognos. Detta examensarbete syftade till att använda gensredigeringsteknologier som CRISPR-interferens (CRISPRi) och RNA-interferens (RNAi) för att störa CAPRIN1-uttryck i HCC-cellinjer och analysera dess effekter på cellproliferation och mängden av CAPRIN1:s främsta RNA-mål. CRISPRi-konstruktioner som riktade sig mot transkriptionsstartstället (TSS) av CAPRIN1 designades och validerades, men trots lyckad kloning och uttryck av guideRNA:er (gRNA:er) resulterade CRISPRi-medierad gensläckning (KD) inte i någon signifikant minskning av CAPRIN1-uttryck. Ineffektiviteten hos CRISPRi tillskrevs låg transfektionseffektivitet, vilket bekräftades av fluorescensmikroskopi med EGFP-expressande plasmider i HepG2- och Huh7-celler. Detta kräver ytterligare optimering av elektroporationsparametrar eller utforskning av alternativa leveransmetoder. I kontrast uppnådde RNAi-medierad KD en betydande minskning av CAPRIN1-uttryck, vilket visade hög KD-effektivitet (90%) enligt RT-qPCR. Denna nivå av gensläckning gav en robust modell för vidare analyser. Efterföljande RT-qPCR av sex topp-RNA-mål identifierade av RAPseq visade varierande svar, med oväntad uppreglering av MYC och Cyclin D2, vilket går emot litteratur som antyder att deras stabilitet beror på CAPRIN1. Denna diskrepans kan förklaras av betydande standardavvikelse i uttrycksnivåerna, vilket understryker behovet av att upprepa experimenten samt genomföra en transkriptomanalys med RNA-seq för att identifiera meningsfulla mål såsom långa icke-kodande RNA (lncRNA:er). Ytterligare, MTT-proliferationstester, visade ökad cellproliferation efter CAPRIN1-KD, även om experimentella inkonsekvenser såsom ojämna cellantal begränsade slutsatsernas pålitlighet. För att erhålla tillförlitliga resultat behöver dock MTT-testet upprepas för att säkerställa konsistens med den positiva kontrollen och samla in statistiskt signifikanta data.Sammanfattningsvis, trots att CRISPRi-försöket stötte på betydande utmaningar, kan gRNA-designen och klonade plasmider användas i framtida studier när elektroporationsprotokollet har optimerats. Dessutom visade den framgångsrika RNAi-medierade KD av CAPRIN1 en alternativ metod som kan antas för vidare studier med andra RBP-kandidater. Framtida studier bör syfta till att optimera elektroporationssystemet, validera KD på proteinnivå och använda RNA-seq för en omfattande analys av CAPRIN1:s inverkan på transkriptomet i HCC-cellinjer. Dessa ansträngningar kommer att förbättra förståelsen av CAPRIN1:s regulatoriska mekanismer och dess potential som terapeutiskt mål vid HCC. / RNA-binding proteins (RBPs) play a crucial role in post-transcriptional gene regulation, and their dysregulation is implicated in cancer pathogenesis. CAPRIN1, a cytoplasmic activation/proliferation-associated protein, identified as an oncofetal RBP with potential significance in hepatocellular carcinoma (HCC), is a worthy candidate to be studied. Objective: This project aimed to establish a protocol for silencing RBPs gene expression via CRISPR interference (CRISPRi) technology using CAPRIN1 as a case study, as the roles of CAPRIN1 in tumorigenesis remains unknown. Results: Despite successful cloning of the designed gRNAs, CRISPRi-mediated knockdown did not reduce CAPRIN1 expression, attributed to low transfection efficiency as indicated by fluorescence microscopy. RNAi-mediated knockdown, however, achieved substantial reduction in CAPRIN1 expression (90%). Subsequent analysis of CAPRIN1 top RNA interactors showed substantial standard deviations, highlighting the need for repeating the experiments. The MTT assay showed uneven initial seeding densities, necessitating further repetitions of the assay. Conclusions: The study highlights the challenges associated with CRISPi-mediated knockdown, especially in transfecting HepG2 cells with large plasmids using electroporation. However, the designed gRNAs and cloned plasmids have the potential to be used in future studies, provided that the transfection process is further optimized. RNAi proved to be an effective alternative for gene silencing, achieving high knockdown efficiency and enabling subsequent analysis of CAPRIN1 target RNAs. Prioritizing further optimization of CRISPRi transfection protocols in upcoming projects will facilitate the adoption of this workflow for investigating other RBP candidates. Additionally, performing a comprehensive RNA-seq analysis could provide a deeper understanding of CAPRIN1’s role in HCC.

No description available.

No description available.

Omkring 20 miljoner nya cancerfall inträffar över hela världen varje år, och under 2020 uppskattades det att 10 miljoner dödsfall var förknippade med cancer. En av de vanligaste behandlingarna för cancer är cytostatika (cellgifter) som angriper alla snabbväxande celler. Detta kan i sin tur leda till allvarliga biverkningar, exempelvis hematologiska toxicitetsreaktioner som kan vara livshotande och till och med dödliga, men hur allvarligt en patient kommer att reagera på behandlingen är mycket individuellt. För närvarande finns det ingen definitiv förklaring på vad som är den bakom- liggande orsaken till dessa allvarliga toxicitetsreaktioner. Det kan vara en genetisk komponent och det antas att genetiska variationer finns i genomets regulatoriska sekvenser som kan vara bidragande faktorer. För detta examensarbete har det identifierats varianter som finns inom eller nära någon enhancer där motsvarande enhancer kan vara kopplad till gener relevanta för de allvarliga toxicitetsreaktioner som vissa patienter upplever. Syftet är att validera att dessa enhancers faktiskt reglerar genuttrycket av dessa gener genom CRISPR-interferens (CRISPRi). Genom att rikta in sig på de identifierade enhancer-varianterna med CRISPRi-systemet, med hjälp av flera olika sgRNA, skulle en mätbar förändring i genuttryck kunna uppnås. Den slutliga valideringen av dessa enhancers, om de faktiskt modulerar genuttrycket, har inte utförts på grund av tidsbrist. Dock  har  alla  nöd- vändiga komponenter förberetts såsom att integrera de erforderliga sekvenserna för CRISPRi till genomet av cancercellinjen K562 och sorterat ut de celler med framgångsrik integrering, därigenom skapat en stabil cellinje. / Around 20 million new cancer cases occur worldwide every year, and in 2020 alone it was estimated that 10 million deaths were associated with cancer. One of the most common treatments for cancer is the use of chemotherapy drugs which are nonspecific and target all fast dividing cells. This in turn can lead to serious haematological toxicity reactions among other adverse side effects that could be life threatening and even fatal, but how severely a patient will react to the treatment is very individual.  As of now there is no definite answer to what the underlying cause for these severe toxicity reactions is.  There could be a genetic component and it is hypothesised that there are variants residing in the regulatory sequences of the genome that could be contributing factors. For this degree project, variants that are located within or near an enhancer have been identified where the corresponding enhancer might be linked to genes relevant for why some patients might experience severe toxicity re- actions. The aim is to validate that these enhancers do in fact regulate the gene expression of these genes through the use of CRISPR-interference (CRISPRi). By targeting around the identified enhancer variants with the CRISPRi system, using several different sgRNA, there could be a measur- able change in gene expression. The final validation of the enhancers, if these do in fact modulate the gene expression, was not performed due to lack of time. However, all necessary components were prepared such as integrating the required sequences for CRISPRi into the genome of the cancer cell line K562 and sort for successful integration, thereby creating a stable cell line.

Derived from and inspired by the adaptive immune system of bacteria, CRISPR has gone from basic biology knowledge to a revolutionizing biotechnological tool, applicable in many research areas such as medicine, industry and agriculture. The full mechanism of CRISPR-Cas9 was first published in 2012 and various CRISPR-Cas systems have already passed the first stages of clinical trials as new gene therapies. The immense research has resulted in continuously growing knowledge of CRISPR systems and the technique seems to have the potential to greatly impact all life on our planet. Therefore, this literature study aims to thoroughly describe the CRISPR-Cas system, and further suggest an undergraduate laboratory exercise involving gene editing with the CRISPR-Cas9 tool. In this paper, we describe the fundamental technical background of the CRISPR-Cas system, especially emphasizing the most studied CRISPR-Cas9 system, its development and applications areas, as well as highlighting its current limitations and ethical concerns. The history of genetic engineering and the discovery of the CRISPR system is also described, along with a comparison with other established gene editing techniques.  This study concludes that a deeper knowledge about CRISPR is important and required since the technique is applicable in many research areas. A laboratory exercise will not only inspire but also provide extended theoretical and practical knowledge for undergraduate students.